International patent classifier
381-1-003 · 76880 yozuv
| Id Eng | Name | |
|---|---|---|
| A61K0031529000 | forming part of bridged ring systems | Learn more |
| A61K0031530000 | having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K0031555000) | Learn more |
| A61K0031535000 | having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines | Learn more |
| A61K0031535500 | Non-condensed oxazines containing further heterocyclic rings | Learn more |
| A61K0031536000 | ortho- or peri-condensed with carbocyclic ring systems | Learn more |
| A61K0031536500 | ortho- or peri-condensed with heterocyclic ring systems | Learn more |
| A61K0031537000 | spiro-condensed or forming part of bridged ring systems | Learn more |
| A61K0031537500 | 1,4-Oxazines, e.g. morpholine | Learn more |
| A61K0031537700 | not condensed and containing further heterocyclic rings, e.g. timolol | Learn more |
| A61K0031538000 | ortho- or peri-condensed with carbocyclic ring systems | Learn more |
| A61K0031538300 | ortho- or peri-condensed with heterocyclic ring systems | Learn more |
| A61K0031538600 | spiro-condensed or forming part of bridged ring systems | Learn more |
| A61K0031539000 | having two or more oxygen atoms in the same ring, e.g dioxazines | Learn more |
| A61K0031539500 | having two or more nitrogen atoms in the same ring, e.g. oxadiazines | Learn more |
| A61K0031540000 | having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame | Learn more |
| A61K0031541000 | Non-condensed thiazines containing further heterocyclic rings | Learn more |
| A61K0031541500 | ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam | Learn more |
| A61K0031542000 | ortho- or peri-condensed with heterocyclic ring systems | Learn more |
| A61K0031545000 | Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine | Learn more |
| A61K0031546000 | containing further heterocyclic rings, e.g. cephalothin | Learn more |
| A61K0031547000 | spiro-condensed or forming part of bridged ring systems | Learn more |
| A61K0031548000 | having two or more sulfur atoms in the same ring | Learn more |
| A61K0031549000 | having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide | Learn more |
| A61K0031550000 | having seven-membered rings, e.g. azelastine, pentylenetetrazole | Learn more |
| A61K0031551000 | having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep | Learn more |
| A61K0031551300 | 1,4-Benzodiazepines, e.g. diazepam | Learn more |
| A61K0031551700 | condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam | Learn more |
| A61K0031553000 | having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine | Learn more |
| A61K0031554000 | having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem | Learn more |
| A61K0031555000 | containing heavy metals, e.g. hemin, hematin, melarsoprol | Learn more |
| A61K0031557000 | Eicosanoids, e.g. leukotrienes | Learn more |
| A61K0031557500 | having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha | Learn more |
| A61K0031557800 | having a pentalene ring system, e.g. carbacyclin, iloprost | Learn more |
| A61K0031558000 | having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes | Learn more |
| A61K0031558500 | having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin | Learn more |
| A61K0031559000 | having heterocyclic rings containing hetero atoms other than oxygen | Learn more |
| A61K0031560000 | Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids | Learn more |
| A61K0031565000 | not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol | Learn more |
| A61K0031566000 | having an oxo group in position 17, e.g. oestrone | Learn more |
| A61K0031567000 | substituted in position 17 alpha, e.g. mestranol, norethandrolone | Learn more |
| A61K0031568000 | substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone | Learn more |
| A61K0031568500 | having an oxo group in position 17, e.g. androsterone | Learn more |
| A61K0031569000 | substituted in position 17 alpha, e.g. ethisterone | Learn more |
| A61K0031570000 | substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone | Learn more |
| A61K0031573000 | substituted in position 21, e.g. cortisone, dexamethasone, prednisone | Learn more |
| A61K0031575000 | substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol | Learn more |
| A61K0031580000 | containing heterocyclic rings, e.g. aldosterone, danazol, stanozolol, pancuronium, digitogenin (digitoxin A61K0031704000) | Learn more |
| A61K0031585000 | containing lactone rings, e.g. oxandrolone, bufalin | Learn more |
| A61K0031590000 | Compounds containing 9,10-seco-cyclopenta[a]hydro- phenanthrene ring systems | Learn more |
| A61K0031592000 | 9,10-Secoergostane derivatives, e.g. ergocalciferol, vitamin D2 | Learn more |
Yangilangan: 23.12.2021